HRP20180301T1 - Postupci liječenja psorijaze uporabom il-17 antagonista - Google Patents

Postupci liječenja psorijaze uporabom il-17 antagonista Download PDF

Info

Publication number
HRP20180301T1
HRP20180301T1 HRP20180301TT HRP20180301T HRP20180301T1 HR P20180301 T1 HRP20180301 T1 HR P20180301T1 HR P20180301T T HRP20180301T T HR P20180301TT HR P20180301 T HRP20180301 T HR P20180301T HR P20180301 T1 HRP20180301 T1 HR P20180301T1
Authority
HR
Croatia
Prior art keywords
secukinumab
patient
psoriasis
treatment
use according
Prior art date
Application number
HRP20180301TT
Other languages
English (en)
Croatian (hr)
Inventor
Achim Guettner
Matthias Machacek
Charis Papavassilis
Oliver Sander
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44759699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20180301(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20180301T1 publication Critical patent/HRP20180301T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20180301TT 2010-10-08 2011-10-07 Postupci liječenja psorijaze uporabom il-17 antagonista HRP20180301T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39138810P 2010-10-08 2010-10-08
EP11764764.4A EP2625199B1 (en) 2010-10-08 2011-10-07 Methods of treating psoriasis using il-17 antagonists
PCT/EP2011/067522 WO2012045848A1 (en) 2010-10-08 2011-10-07 Methods of treating psoriasis using il-17 antagonists

Publications (1)

Publication Number Publication Date
HRP20180301T1 true HRP20180301T1 (hr) 2018-03-23

Family

ID=44759699

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180301TT HRP20180301T1 (hr) 2010-10-08 2011-10-07 Postupci liječenja psorijaze uporabom il-17 antagonista

Country Status (28)

Country Link
US (9) US9717791B2 (enExample)
EP (4) EP2625199B1 (enExample)
JP (2) JP5537740B2 (enExample)
KR (3) KR20150018595A (enExample)
CN (2) CN103154031A (enExample)
AU (1) AU2011311482B2 (enExample)
BR (1) BR112013008501A2 (enExample)
CA (1) CA2813900C (enExample)
CL (1) CL2013000930A1 (enExample)
CY (1) CY1119942T1 (enExample)
DK (1) DK2625199T3 (enExample)
ES (1) ES2660770T3 (enExample)
HK (1) HK1247932A1 (enExample)
HR (1) HRP20180301T1 (enExample)
HU (1) HUE038334T2 (enExample)
IL (1) IL225310A (enExample)
LT (1) LT2625199T (enExample)
MA (1) MA34646B1 (enExample)
MX (1) MX356279B (enExample)
NO (1) NO2625199T3 (enExample)
PH (1) PH12013500660B1 (enExample)
PL (1) PL2625199T3 (enExample)
PT (1) PT2625199T (enExample)
RU (2) RU2665954C1 (enExample)
SG (1) SG188979A1 (enExample)
SI (1) SI2625199T1 (enExample)
TW (2) TWI548419B (enExample)
WO (1) WO2012045848A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EP2523688B1 (en) 2010-01-15 2017-10-11 Kirin-Amgen, Inc. Antibody formulation and therapeutic regimens
RU2012149227A (ru) 2010-05-20 2014-06-27 Аблинкс Нв Биологические материалы, относящиеся к her3
LT3757126T (lt) 2010-11-05 2025-12-10 Novartis Ag Psoriazinio artrito gydymo būdas, panaudojant il-17 antagonistus
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
JP2015504430A (ja) * 2011-11-21 2015-02-12 ノバルティス アーゲー Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法
CN105307675A (zh) * 2013-03-15 2016-02-03 美国安进公司 使用抗il23抗体治疗克罗恩氏病的方法
HK1219425A1 (zh) * 2013-03-15 2017-04-07 Amgen Inc. 使用抗il-23抗体治疗银屑病的方法
US10434172B2 (en) 2013-08-15 2019-10-08 Novartis Ag Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists
CN106132433B (zh) * 2013-12-27 2021-04-06 国立大学法人大阪大学 以il-17a作为靶标的疫苗
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
WO2015153144A1 (en) * 2014-03-31 2015-10-08 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
CN107072955B (zh) 2014-05-15 2021-06-18 拉尼医疗有限公司 包含多肽和/或蛋白质的固体块的药物组合物和该固体块的制备方法
US11548940B2 (en) * 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
KR102427097B1 (ko) * 2014-08-26 2022-08-01 암젠 케이-에이, 인크. 항-tnf-알파 항체 요법을 받은 건선 환자의 치료 방법
CN115944734A (zh) * 2014-09-10 2023-04-11 诺华股份有限公司 使用il-17拮抗剂抑制银屑病关节炎患者的结构损伤进展
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
CA2978431C (en) 2015-03-02 2023-10-24 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
CN108350068A (zh) 2015-10-27 2018-07-31 Ucb生物制药私人有限公司 使用抗-il-17a/f抗体的治疗方法
WO2018015880A1 (en) 2016-07-19 2018-01-25 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
JP2019505516A (ja) * 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
WO2018158741A1 (en) * 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
CN111032691A (zh) * 2017-08-23 2020-04-17 伊莱利利公司 生殖器银屑病的治疗
TWI808397B (zh) * 2018-09-11 2023-07-11 美商美國禮來大藥廠 治療牛皮癬之方法
CN114127108A (zh) 2019-07-30 2022-03-01 江苏恒瑞医药股份有限公司 Il-17拮抗剂治疗自身免疫疾病的方法
AU2020347952A1 (en) 2019-09-20 2022-04-07 Novartis Ag Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists
EP4289863A4 (en) * 2020-12-17 2025-04-09 Shanghai Huaota Biopharmaceutical Co., Ltd. BISPECIFIC ANTIBODY AGAINST IL-17A AND IL-36R AND USE THEREOF
WO2022184114A1 (zh) * 2021-03-03 2022-09-09 苏州盛迪亚生物医药有限公司 抗il-17抗体治疗自身免疫性疾病和炎症的方法
WO2023186174A1 (en) * 2022-04-01 2023-10-05 Zai Lab (Shanghai) Co., Ltd. Topical formulation comprising an il-17a binding molecule and uses thereof
CN116593718B (zh) * 2023-07-18 2023-09-15 军科正源（北京）药物研究有限责任公司 用于检测司库奇尤单抗抗药性抗体的试剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US6093745A (en) * 1997-11-25 2000-07-25 Psorx, L.L.C. Methods and composition for treating skin proliferative diseases
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
TW201705980A (zh) * 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP2116258A1 (en) * 2005-09-01 2009-11-11 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
DK1963368T6 (da) * 2005-12-13 2020-06-29 Lilly Co Eli Anti-il-17-antistoffer
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
RU2367429C2 (ru) 2007-01-30 2009-09-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения псориаза
WO2008150490A2 (en) * 2007-06-01 2008-12-11 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriasis and crohn's disease
RU2341272C1 (ru) * 2007-10-22 2008-12-20 Левон Никитович Мкртчян Средство для неспецифической иммунотерапии
ES2493042T3 (es) 2008-09-29 2014-09-11 Roche Glycart Ag Anticuerpos contra la IL-17 humana y usos de los mismos

Also Published As

Publication number Publication date
JP2014114288A (ja) 2014-06-26
JP5537740B2 (ja) 2014-07-02
ES2660770T3 (es) 2018-03-26
IL225310A (en) 2016-10-31
KR20150018595A (ko) 2015-02-23
BR112013008501A2 (pt) 2016-08-16
TW201630625A (zh) 2016-09-01
WO2012045848A1 (en) 2012-04-12
US10583190B2 (en) 2020-03-10
CA2813900C (en) 2017-01-10
PT2625199T (pt) 2018-02-28
MA34646B1 (fr) 2013-11-02
SI2625199T1 (en) 2018-03-30
CN103154031A (zh) 2013-06-12
PH12013500660A1 (en) 2013-05-20
DK2625199T3 (en) 2018-02-26
JP2013543501A (ja) 2013-12-05
US20210113688A1 (en) 2021-04-22
HK1247932A1 (en) 2018-10-05
CN107029234A (zh) 2017-08-11
US20200171147A1 (en) 2020-06-04
EP3792281A1 (en) 2021-03-17
US20230321231A1 (en) 2023-10-12
TWI564022B (zh) 2017-01-01
US20250161444A1 (en) 2025-05-22
TW201216984A (en) 2012-05-01
EP4137514A1 (en) 2023-02-22
MX356279B (es) 2018-05-22
EP2625199B1 (en) 2017-11-22
NO2625199T3 (enExample) 2018-04-21
US20170304439A1 (en) 2017-10-26
CL2013000930A1 (es) 2014-03-28
AU2011311482B2 (en) 2014-05-29
HUE038334T2 (hu) 2018-10-29
US9717791B2 (en) 2017-08-01
AU2011311482A1 (en) 2013-04-04
US20210162044A1 (en) 2021-06-03
US20250161445A1 (en) 2025-05-22
CA2813900A1 (en) 2012-04-12
PH12013500660B1 (en) 2017-10-27
KR20140097566A (ko) 2014-08-06
US20250161443A1 (en) 2025-05-22
RU2013120957A (ru) 2014-11-20
EP2625199A1 (en) 2013-08-14
SG188979A1 (en) 2013-05-31
KR20130110179A (ko) 2013-10-08
CY1119942T1 (el) 2018-12-12
RU2665954C1 (ru) 2018-09-05
KR101620771B1 (ko) 2016-05-12
EP3299390A1 (en) 2018-03-28
US20130202610A1 (en) 2013-08-08
PL2625199T3 (pl) 2018-04-30
TWI548419B (zh) 2016-09-11
IL225310A0 (en) 2013-06-27
US11534490B2 (en) 2022-12-27
RU2591083C2 (ru) 2016-07-10
LT2625199T (lt) 2018-03-12
MX2013003916A (es) 2013-06-03

Similar Documents

Publication Publication Date Title
HRP20180301T1 (hr) Postupci liječenja psorijaze uporabom il-17 antagonista
HRP20191162T1 (hr) Postupci liječenja ankilozantnog spondilitisa uporabom anti-il-17 protutijela
JP2012180381A5 (enExample)
BRPI0719009B8 (pt) mecanismo de dosagem e acionamento destinado a dispositivos de liberação de fármacos
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
NO20092323L (no) Doserings- og drivmekanisme for legemiddelleveringsanordning
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
CY1124734T1 (el) Μορφες δοσολογιας αυξητικης ορμονικης μακρας δρασης
BR112014030404A2 (pt) proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento
MX390570B (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
MX388093B (es) Dosis y regimen para inhibidores de la interaccion hdm2-p53.
MX386380B (es) Forma de dosis de disolución rápida de vacuna oral que usa almidón.
HRP20180468T1 (hr) Novi derivat analoga inzulina
FI2683245T4 (fi) Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä
MX390667B (es) Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
CY1120176T1 (el) Μεθοδος για τη μειωση των συμπτωματων που μοιαζουν με αυτα της γριπης που συνδεονται με ενδομυϊκη χορηγηση ιντερφερονης με τη χρηση ενος σχηματος κλιμακουμενης δοσολογιας ταχειας τιτλοδοτησης
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
HRP20250052T1 (hr) Postupak liječenja multiple skleroze
MX387263B (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma.
HK1244231A1 (zh) 使用hcg治疗慢性疼痛的方法和治疗
HRP20160811T1 (hr) Upotreba odiparcila u liječenju mukopolisaharidoze
MX2016006375A (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
UA115803U (xx) Спосіб лікування вертеброгенних радикулопатій
MD4231B1 (en) Medicament based on troxerutin and carbazochrome for the treatment of portal gastropathies in hepatic cirrhosis